The company becomes the third in two months to buy back a division it had spun out just a few years earlier.
Preliminary data on its pan-cancer blood test appear surprisingly competitive.
The sequencing group’s $8bn deal to recapture Grail leaves shareholders unimpressed.
The first pan-cancer approval might have gone to Guardant, but Roche’s subsidiary’s blood test appears to be able to find more markers.
Fortunately for medical device start-ups, it takes more than a pandemic to put venture capitalists off doing deals.
Liquid biopsy developer Grail exemplifies 2020’s trend of sizeable mid-stage financings.
Thrive is in some ways ahead of the competition with the first-ever screening trial of a liquid biopsy, but the test’s sensitivity leaves something to be desired.